Iterum Therapeutics PLC

NASDAQ ITRM

Download Data

Iterum Therapeutics PLC Price to Book Ratio (P/B) on June 03, 2024: -3.85

Iterum Therapeutics PLC Price to Book Ratio (P/B) is -3.85 on June 03, 2024, a -591.80% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
  • Iterum Therapeutics PLC 52-week high Price to Book Ratio (P/B) is 1,851.85 on August 09, 2023, which is 48,208.08% above the current Price to Book Ratio (P/B).
  • Iterum Therapeutics PLC 52-week low Price to Book Ratio (P/B) is -4.33 on May 09, 2024, which is -12.59% below the current Price to Book Ratio (P/B).
  • Iterum Therapeutics PLC average Price to Book Ratio (P/B) for the last 52 weeks is 9.86.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

USD 1.17

0.00%

StockViz Staff

September 8, 2024

Any question? Send us an email